Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host
Disease area: Airway diseases, Respiratory infections

Abstract

Introduction: In mild and moderate COPD (Gold I-II), the typically described pathogenic bacteria causing exacerbations are S. pneumoniae, H. influenzae and M. catarrhalis. In our COPD population, increasing and unexpected types of bacteria were detected in an informal series of cases. Objective: To determine the prevalence of uncommon pathogenic bacteria in mild exacerbations of stable COPD outpatients.
Methods: During a two-year period (2006-2007) 150 consecutive outpatients attending for a mild exacerbation were studied. Sputum sample for bacteriologic evaluation was obtained in 78 subjects with COPD GOLD II (FEV1 62±24) and mean age 69±8 years. 48 (61%) were ex-smokers with 49±34 pack years index, and 30 (39%) had biomass exposure with 239 hours/year of exposure.
Results: 47% sputum specimens had no bacterial growth. From the 53% positive cultures, in 9 more than one pathogenic bacterium was observed. In 50% the most common bacteria were isolated: H. influenzae, 20%; M. catarrhalis, 16% and S. pneumoniae, 14%. Of note, P. aeruginosa was isolated in 16% of the samples and in 30% gram negative enteric bacilli were isolated: K. pneumonaie, 6%; K. oxytoc, 6%; E. coli, 4%; E. cloacae, 8%; S. marcescens, 6%; and others (S. aureus and A. baumanii), 4%. There were no significant associations between the bacteria type, FEV1, age and risk exposure.
Conclusions: In contrast to previous information, stable COPD outpatients show a high prevalence of unexpected gram negative enteric bacilli and pseudomonas in a mild exacerbation of early stages of COPD. This information may be relevant for prescribing antibiotics in a local setting.

Rating:

Share or cite this content

Citations should be made in the following way:
J. Padua, A. Ramirez-Venegas, R. J. Hernandez-Zenteno, C. Sanchez-Romero, F. Quinones-Falconi, R. H. Sansores-Martinez (Mexico City/DF, Mexico). High prevalence of gramnegative enteric bacilli and pseudomonas in mild exacerbation of early stages COPD (Gold I-II). Eur Respir J 2008; 32: Suppl. 52, 2300

Member's Comments

No comment yet.

Related content which might interest you: High mortality in COPD patients with isolation of aspergillus spp in bronchial secretions Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Low blood eosinophil count is associated with gram-positive cocci infection and poor clinical outcomes in severe exacerbations of COPD Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases Year: 2020 Antimicrobial profile and bacterial resistance in patients wit acute exacerbation of COPD, an Upper Egypt multicenters experience Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Evolution of antimicrobial susceptibility of respiratory isolates in chronic obstructive pulmonary patients diagnosed of acquired community pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Influence of biofim on the bronchial microbiome in COPD patients colonized or infected by pseudomonas aeruginosa Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Source: Eur Respir J 2009; 34: 1072-1078 Year: 2009 The impact of pseudomonas aeruginosa in the sputum of patients presenting with acute COPD exacerbation Source: Annual Congress 2004 - Role of infection in COPD Year: 2004 Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa: resistance to common antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 540s Year: 2001 Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: 240-244 Year: 2007 Common and atypical pathogens in severe COPD exacerbations and predictors of positive sputum cultures Source: Annual Congress 2010 - Colonisation and infection in COPD Year: 2010 Telithromycin displays high clinical efficacy in outpatients with mild to moderate community-acquired pneumonia caused by atypical/intracellular pathogens Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003 Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002 Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004 Serum procalcitonin (PCT-Q) as a diagnostic tool for bacterial lower respiratory tract infection among COPD patients with acute exacerbation Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Etiology of exacerbations in severe COPD patients with bronchial chronic colonization by pseudomonas Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Bacterial infections in patients with acute exacerbations of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004 Disseminated bacterial community-acquired pneumonia in patients at late stages of HIV infection Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019